Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...
NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...
As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, ...
Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...
Israeli drug manufacturer Teva Pharmaceutical Industries has resumed the deliveries of the scarce epilepsy drug Finlepsin ...
23h
Catalyst Pharmaceuticals Inc (CPRX) reports a robust 28.3% revenue increase in Q4 2024, driven by strong product performance ...
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback